证券代码：002919 证券简称：名臣健康 公告编号：2023-035 名臣健康用品股份有限公司 关于持股 5%以上股东协议转让股份完成 过户登记的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本次股份协议转让的基本情况 名臣健康用品股份有限公司（以下简称"公司"、"名臣健康"） 持股 5% 以上股东刘晓伟于 2023 年 6 月 21 日与吴心玲签署了《股份转让协议》，刘晓伟 拟将其持有的 12,219,353 股公司股份（占公司目前总股本的 5.50%）协议转让 给吴心玲。具体内容详见公司于 2023 年 6 月 22 日在《中国证券报》、《上海证券 报》、《证券时报》、《证券日报》和巨潮资讯网（www.cninfo.com.cn）披露的《关 于持股 5%以上股东协议转让公司部分股份的提示性公告》（公告编号为： 2023-028）、《关于持股 5%以上股东股份协议转让的提示性公告的更正公告》（公 告编号为：2023-029）及在巨潮资讯网（www.cninfo.com.cn）披露的《简式权 益变动报告书（一）》、《简式权益变动报告书（二）》。 ...

证券代码:002919 证券简称:名臣健康 编号:2023-002 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 其他(2023广东辖区上市公司投资者集体接待日) 参与单位名称 投资者网上提问 时间 2023年9月19日15:45-17:00 方式 公司通过全景网"投资者关系互动平台"(https://ir.p5w.net) 采用网络远程的方式召开业绩说明会 公司董事长、总经理陈建名 上市公司接待人 公司副董事长、副总经理、财务总监彭小青 员姓名 公司董事、副总经理、董事会秘书陈东松 投资者提出的问题及公司回复情况 公司就投资者在本次说明会中提出的问题进行了回复 投资者关系活动 1、请问贵司什么时候能到达市值100亿 主要内容介绍 答:您好,公司希望能够做强做优做大,能够给投资者带来更 好的回报,100 亿还远不是我们的目标,感谢您的关注! 附件清单(如有) 无 日期 2023年9月19日 投资者关系活动记录表 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 844,585,892.73, representing a 145.11% increase compared to CNY 344,578,465.20 in the same period last year[20]. - Net profit attributable to shareholders reached CNY 99,642,930.15, a significant increase of 267.05% from CNY 27,146,609.00 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was CNY 98,825,203.27, up 389.46% from CNY 20,190,495.82 year-on-year[20]. - Basic earnings per share increased to CNY 0.45, a rise of 275.00% compared to CNY 0.12 in the same period last year[20]. - The company reported a total profit of CNY 81,398,181.13 for the first half of 2023, compared to CNY 24,140,544.12 in the same period of 2022, an increase of 237.5%[140]. - The total revenue of Guangdong Mingchen Daily Chemical Co., Ltd. for the reporting period was ¥226,105,622.08, with a net profit of ¥10,082,352.64[57]. - The company reported a significant decrease in cash and cash equivalents by 94,761,645.64 CNY compared to the previous period[148]. Assets and Liabilities - The total assets of the company at the end of the reporting period were CNY 1,305,348,384.57, reflecting a 5.01% increase from CNY 1,243,033,194.99 at the end of the previous year[20]. - The total liabilities decreased to CNY 466,457,573.88 from CNY 503,785,314.45, a reduction of approximately 7.4%[134]. - The company’s cash and cash equivalents decreased to ¥81,371,573.20, representing 6.23% of total assets, down from 10.94% in the previous year[44]. - The company reported a decrease in total assets to 4.8 billion, down from 5.1 billion in the previous period[154]. - The total equity attributable to shareholders at the end of the reporting period was 1.5 billion, reflecting a decrease from the previous period[156]. Business Segments - The company operates in two main business segments: daily chemical products and gaming, with a focus on health care products such as shampoos and skin care items[28]. - The gaming segment has developed a diverse portfolio of games, including titles like "Kingdom of Heroes" and "Zhenhun Street: Born to be King," with a focus on self-developed and self-published games[29]. - The daily chemical segment includes major brands like Ti Hua Zhi Xiu and Mei Wang, which are recognized as famous trademarks in Guangdong Province[31]. Research and Development - The company has established a comprehensive R&D system, holding 1,051 trademarks, 53 invention patents, and 88 design patents, positioning itself as a leader in local daily chemical product innovation[34]. - Research and development expenses rose by 26.83% to ¥63,139,913.44, up from ¥49,782,843.77, due to increased personnel costs and design expenses for game development[39]. - The company is investing in R&D, allocating 8% of its revenue towards the development of new technologies[185]. Market Strategy and Growth - The company aims to enhance its market competitiveness through strategic acquisitions and partnerships in the gaming industry, having established a wholly-owned subsidiary for game publishing[30]. - Future growth strategies include expanding product lines and enhancing brand recognition in both daily chemical and gaming sectors[28]. - The company plans to continue expanding its product offerings and market presence, leveraging its strong R&D capabilities and operational efficiency[35]. - The company is focusing on expanding its market presence in Asia, aiming for a 15% increase in market share by the end of 2024[154]. Risks and Governance - The management highlighted potential risks and countermeasures in the future operations, which investors should be aware of[3]. - The company faces risks related to brand image infringement, which could negatively impact its reputation and financial performance if not effectively managed[62]. - The company has maintained a strict governance structure to protect investor rights, ensuring transparency and adherence to legal requirements in information disclosure[73]. Shareholder Information - Major shareholder Chen Qinfang holds 35.02% of the shares, with a total of 77,812,170 shares, and an increase of 14,541,270 shares during the reporting period[117]. - The company has not experienced any changes in its controlling shareholder during the reporting period, indicating stability in ownership[122]. - The total number of shares held by the top ten unrestricted shareholders amounts to 122,000,000 shares, showcasing concentrated ownership[119]. Future Outlook - The management has provided a guidance of 5% revenue growth for the second half of 2023, despite the current downturn[154]. - The company provided a positive outlook for the next quarter, projecting a revenue growth of 10% to 12%[185]. - Future guidance suggests a cautious outlook due to current cash flow challenges and market conditions[151].

关于名臣健康用品股份有限公司 2022 年年报问询函的回复 致同会计师事务所（特殊普通合伙） 致同会计师事务所（特殊普通合伙） 中国北京朝阳区建国门外大街 22号 赛特广场 5层邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 关于名臣健康用品股份有限公司 2022 年年报问询函的回复 致同专字（2023）第 351A015282 号 深圳证券交易所： 致同会计师事务所（特殊普通合伙）（以下简称"我们"）接受委托对名 臣健康用品股份有限公司（以下简称"公司"或"名臣健康"）2022 年财务报 表，包括 2022 年 12 月 31 日的合并及公司资产负债表，2022 年度的合并及公司利 润表、合并及公司现金流量表、合并及公司股东权益变动表以及相关财务报表附 注进行审计，并于 2023 年 4 月 26 日出具了致同审字（2023）第 351A015921 号的 无保留意见审计报告。 我们于 2023 年 7 月 3 日收到了公司转来的深圳证券交易所（以下简称"深 交所"）出具的《关于对名臣健康用品股份有限公司 2022 ...

名臣健康用品股份有限公司 关于深圳证券交易所对公司 2022 年年报 问询函回复的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：002919 证券简称：名臣健康 公告编号：2023-033 （1）请结合行业特点、公司业务开展情况、产品类别、收入和成本构成、 费用等因素说明你公司 2022 年扣非后净利润大幅下降的原因。 深圳证券交易所： 名臣健康用品股份有限公司（以下简称 "公司"）于 2023 年 7 月 3 日收到 贵所下发的《关于对名臣健康用品股份有限公司 2022 年年报的问询函》（公司 部年报问询函〔2023〕第 376 号）（以下简称"《问询函》"）。我们就问询函 所提问题逐条进行了认真分析及讨论，按贵所要求现回复如下： 1、年报显示，2022 年度你公司实现营业收入 94,540.49 万元，同比上升 27.05%，实现净利润2,532.98万元，同比下降81.03%，实现扣非后净利润-477.37 万元，同比下降 104.36%。 公司回复： 本年公司营业收入增加主要系发力游戏发行业务，公司通过收并购、新设等 方式组建了多个游 ...

非经营性资金 占用 资金占 用方名 称 占用方与 上市公司 的关联关 系 上市公司 核算的会 计科目 2023 年半年 度期初占用 资金余额 2023 年半 年度占用 累计发生 金额（不 含利息） 2023 年半年 度占用资金 的利息(如 有) 2023 年半年 度偿还累计 发生金额 2023 年半年 度期末占用 资金余额 占用形 成原因 占用 性质 控股股东、实 际控制人及其 附属企业 0.00 0.00 小计 - - - 0.00 0.00 0.00 0.00 0.00 - - 前控股股东、 实际控制人及 其附属企业 0.00 0.00 小计 - - - 0.00 0.00 0.00 0.00 0.00 - - 其他关联方及 附属企业 0.00 0.00 小计 - - - 0.00 0.00 0.00 0.00 0.00 - - 总计 - - - 0.00 0.00 0.00 0.00 0.00 - - | | 资金往 | 往来方与 | 上市公司 | 2023 | 年半年 | 2023 年半 年度占用 | 2023 年半年 | 2023 | 年半年 | 2023 年半年 | | | | --- | --- ...

名臣健康用品股份有限公司 独立董事关于控股股东及其他关联方占用公司资金、公司对外担保 情况的专项说明和独立意见 （以下无正文，为《名臣健康用品股份有限公司独立董事关于控股股东及其他 关联方占用公司资金、公司对外担保情况的专项说明和独立意见》签署页） 以下为独立董事签署： 朱水宝 二〇二三年八月二十九日 _______________ （以下无正文，为《名臣健康用品股份有限公司独立董事关于控股股东及其他 关联方占用公司资金、公司对外担保情况的专项说明和独立意见》签署页） 根据《公司法》、《上市公司监管指引第 8 号--上市公司资金往来、对外担保 的监管要求》（[2022]26 号）、《上市公司独立董事规则》及《公司章程》等有关 规定，作为公司独立董事，对公司 2023 年半年度控股股东及其他关联方占用资 金及公司对外担保的情况，基于我们的独立判断，就相关情况作出说明并发表独 立意见如下： 一、 关于 2023 年半年度关联方资金占用及担保情况的专项说明及独立意见 经核查，我们认为： 1、报告期内，公司不存在控股股东及其他关联方占用及变相占用公司资金 的情况。 2、报告期内，公司不存在为控股股东及其他关联方提供担 ...

Financial Performance - The company's operating revenue for 2022 was CNY 945,404,947.07, representing a 27.05% increase compared to CNY 744,148,561.43 in 2021[20]. - The net profit attributable to shareholders of the listed company decreased by 81.03% to CNY 25,329,765.93 from CNY 133,493,915.47 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -4,773,721.00, a decline of 104.36% compared to CNY 109,582,759.28 in 2021[20]. - The basic earnings per share dropped by 80.77% to CNY 0.15 from CNY 0.78 in the previous year[20]. - The cash flow from operating activities for 2022 was CNY 73,251,531.12, a decrease of 8.28% from CNY 79,866,171.40 in 2021[20]. - The weighted average return on net assets was 3.40%, down from 18.96% in the previous year, indicating a significant decline in profitability[20]. - In 2022, the company achieved a total revenue of CNY 945.40 million, representing a year-on-year growth of 27.05%[39]. - The company's net profit attributable to shareholders decreased by 81.03% to CNY 25.33 million in 2022[40]. - The company's operating cash flow decreased by 8.28% to CNY 73.25 million in 2022[40]. Business Model and Strategy - The company has shifted its business model from primarily daily chemical products to a dual main business model including daily chemical products and online gaming through acquisitions[18]. - The company is focusing on expanding its marketing channels, particularly through e-commerce and live streaming sales, to adapt to changing consumer behaviors[31]. - The company aims to enhance its brand presence in third and fourth-tier cities, leveraging local characteristics to build a strong national brand[36]. - The company is actively expanding its market presence and enhancing its product lineup to adapt to changing consumer preferences and trends[58]. - The company plans to strengthen traditional distribution channels and enhance retail network construction to drive sales growth in urban areas[90]. - The company intends to expand its overseas market presence, particularly in Japan and South Korea, while also exploring other international markets[91]. Research and Development - The company reported a total of 49 invention patents, showcasing its strong R&D capabilities in the daily chemical products sector[35]. - The company has developed a comprehensive R&D system and holds 1,127 independent intellectual property rights, including 49 invention patents and 88 design patents[37]. - The company’s research and development investment increased by 11.93% to CNY 110.26 million in 2022[40]. - Research and development expenses increased by 11.93% to 110.26 million in 2022, reflecting the company's commitment to innovation[56]. - The company has completed significant R&D projects, including a new plant-based mosquito repellent and a sulfate-free scalp repair product, aimed at enhancing product performance and market differentiation[56]. Market and Industry Trends - The Chinese gaming industry saw a market size of approximately ¥265.88 billion in 2022, reflecting a year-on-year decline of 10.3%[32]. - The user base for the gaming industry in China reached 664 million in 2022, a slight decrease of 0.3% compared to the previous year[32]. - The domestic daily chemical market has seen increased penetration rates and intensified competition, impacting the company's strategic decisions[79]. - The company has acknowledged significant changes in the domestic daily chemical market, leading to increased competition and a reassessment of marketing strategies[77]. Corporate Governance - The company has established a robust corporate governance structure to ensure compliance and protect shareholder rights[97]. - The company held a total of 5 board meetings during the reporting period, adhering to legal and regulatory requirements[99]. - The company has established independent financial management systems, ensuring no shared bank accounts or mixed tax obligations with shareholders[102]. - The company’s independent directors actively protect the interests of minority shareholders and provide independent opinions on significant matters[99]. - The company’s governance structure aligns with legal and regulatory requirements, with no significant discrepancies noted[99]. Shareholder and Capital Management - The company distributed cash dividends of RMB 36,640,723.5, amounting to RMB 3 per 10 shares, and increased its total share capital to 170,990,043 shares through a capital reserve transfer of 4 shares for every 10 shares held[129]. - The company’s profit available for distribution to shareholders was reported at RMB 274,063,112.59[131]. - The company plans to repurchase shares with a total fund of no less than CNY 50 million and no more than CNY 100 million, at a price not exceeding CNY 35.00 per share[177]. - The company’s major shareholder, Chen Qinfang, holds 63,270,900 shares, representing a significant portion of the total shares[197]. Operational Efficiency - The company completed the acquisition of 100% equity in Guangzhou Ice Wing Network Technology Co., Ltd. for 5 million, with the purchase date set on March 31, 2022[50]. - The company approved the transfer of assets related to its daily chemical business to its wholly-owned subsidiary, Guangdong Mingchen Daily Chemical Co., Ltd., effective June 30, 2022, to enhance operational efficiency and resource allocation[180]. - The company has implemented a cash dividend policy, with the 2021 profit distribution plan executed in June 2022, and the 2022 profit distribution proposal approved by the board, pending shareholder meeting approval[143]. Employee Management - The total number of employees at the end of the reporting period is 2,025, with 2,016 from major subsidiaries[125]. - The professional composition includes 610 technical personnel, 582 sales personnel, and 455 production personnel[126]. - The company emphasizes a "people-oriented" employment philosophy, focusing on talent development and employee rights protection[145]. - The company has focused on enhancing employee capabilities through a structured training program aimed at improving management skills[128]. Legal and Compliance - The company has not reported any issues or violations regarding the use of fundraising funds, ensuring compliance with disclosure requirements[80]. - The company did not experience any major litigation or arbitration matters during the reporting period[159]. - The company has no significant related party transactions during the reporting period[161].

Financial Performance - The company's revenue for Q1 2023 reached ¥406,772,539.06, representing a 172.98% increase compared to ¥149,012,185.35 in the same period last year[5] - Net profit attributable to shareholders was ¥34,104,153.62, up 1,981.81% from ¥1,638,200.89 in Q1 2022[5] - The net profit after deducting non-recurring gains and losses was ¥33,521,743.74, a 2,385.64% increase from ¥1,348,618.09 in the previous year[5] - The company's basic and diluted earnings per share both increased to ¥0.20, a 1,900.00% rise from ¥0.01 in Q1 2022[5] - Operating profit for the quarter was ¥24,659,339.14, compared to just ¥1,050,322.55 in Q1 2022, indicating a substantial improvement in profitability[22] - Net profit attributable to the parent company was ¥34,104,153.62, a remarkable increase from ¥1,638,200.89 in the previous year, reflecting a year-over-year growth of over 1965%[22] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥1,264,401,026.81, a 1.72% increase from ¥1,243,033,194.99 at the end of the previous year[5] - The company's total assets as of March 31, 2023, amount to CNY 1,264,401,026.81, an increase from CNY 1,243,033,194.99 at the beginning of the year[18] - Total current assets are reported at CNY 677,626,885.64, compared to CNY 638,873,323.41 at the beginning of the year, reflecting an increase of approximately 6.0%[17] - Total non-current assets decreased to CNY 586,774,141.17 from CNY 604,159,871.58, a decline of about 2.0%[18] - Total liabilities amount to CNY 491,048,992.65, down from CNY 503,785,314.45, indicating a reduction of approximately 2.5%[18] - The total equity remains stable at CNY 773,352,033.16, unchanged from the previous reporting period[18] Cash Flow - Cash flow from operating activities improved to -¥59,671,619.97, a 15.36% improvement compared to -¥70,501,835.42 in Q1 2022[13] - The cash inflow from operating activities totaled ¥399,260,552.94, compared to ¥165,458,573.09 in the same period last year, indicating improved cash generation capabilities[23] - The net cash flow from investing activities was -2,100,092.89, compared to -65,252,988.05 in the previous period[25] - The total cash outflow from financing activities was 4,657,413.14, with a net cash flow from financing activities of -4,657,413.14, down from -1,065,710.00 previously[25] - The net increase in cash and cash equivalents was -66,429,126.00, compared to -136,820,533.47 in the prior period[25] - The ending balance of cash and cash equivalents was 68,987,820.59, down from 114,077,895.54 in the previous period[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 5,977[14] - The largest shareholder, Chen Qinfang, holds 37.00% of the shares, totaling 63,270,900 shares[14] Expenses - Sales expenses surged by 896.91% to ¥159,736,843.38, driven by higher promotional expenditures related to the growth of the gaming business[12] - Research and development expenses increased to ¥31,582,395.46 from ¥24,383,528.86, indicating a focus on innovation and product development[21] - The company reported a total operating cost of ¥379,638,664.04, which is significantly higher than ¥142,910,650.51 from the previous year, primarily driven by increased sales expenses[21] Other Income - The company reported a significant increase in other income, which rose by 144.78% to ¥743,157.00, attributed to increased input tax deductions[12] Return on Equity - The weighted average return on equity improved to 4.51%, up from 0.22% in the same period last year[5] Inventory - The company's inventory increased to CNY 208,640,338.46 from CNY 191,289,119.65, reflecting an increase of about 9.1%[17] Audit Status - The company’s first-quarter report was not audited[26]